Half-year report · Q2
4480.TEDINET S100WJ2N
Period2025-01-01 → 2025-06-30
Filed2025-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.5bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥29.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥14.7bn | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Operating income | ¥1.5bn | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Operating income | ¥2.3bn | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Ordinary income | ¥1.6bn | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥4.1bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.8bn | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.2bn | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥647m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.8bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥647m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Total assets | ¥47.4bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥45.2bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥42.2bn | at 2024-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥29.4bn | at 2025-06-30 | Cons. | Liabilities |
| Total liabilities | ¥25.0bn | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥18.1bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥20.2bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥19.5bn | at 2024-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.5bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥19.0bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.5bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥19.0bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.9bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.4bn | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.9bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.5bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.3bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.7bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.2bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥11.9bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥11.1bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥20.05 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥86.17 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.9 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥19.95 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥85.62 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥61.5 | 2024-01-01 → 2024-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 38.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.7% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.1% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥1m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥2.9bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥4.5bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥4.5bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥51m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥589m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥589m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥349m |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥13.4bn |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥13.4bn |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥1m |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥4.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥18.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥18.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥1m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | ¥4.4bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-06-30 | −¥2m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-06-30 | −¥2m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥2.2bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥3.6bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥3.6bn |
| jpcrp040300-q2r_E33586-000Medical Platform Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥43m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥239m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥239m |
| jpcrp040300-q2r_E33586-000New Business Development Servicesreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥132m |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥10.9bn |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥10.9bn |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥2m |
| jpcrp040300-q2r_E33586-000Recruitment Platform Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥4.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-06-30 | ¥14.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-06-30 | ¥14.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥2m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-06-30 | ¥4.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 534
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E33586-000MedicalPlatformBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E33586-000NewBusinessDevelopmentServicesReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -1000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E33586-000RecruitmentPlatformBusinessReportableSegmentMember | 13409000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E33586-000MedicalPlatformBusinessReportableSegmentMember | 4468000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E33586-000NewBusinessDevelopmentServicesReportableSegmentMember | 589000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 18467000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -1000000 | JPY |
| Net sales | CurrentYTDDuration | 18465000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E33586-000RecruitmentPlatformBusinessReportableSegmentMember | 4810000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E33586-000MedicalPlatformBusinessReportableSegmentMember | -51000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E33586-000NewBusinessDevelopmentServicesReportableSegmentMember | -349000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 4410000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -2949000000 | JPY |
| Operating income | CurrentYTDDuration | 1461000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の5第1項の表の第1号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-08-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第17期中(自 2025年1月1日 至 2025年6月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社メドレー | |
| Company name in english cover page | FilingDateInstant | ＭＥＤＬＥＹ，ＩＮＣ. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 瀧口 浩平 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区六本木六丁目10番1号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-6372-1265 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役 上級執行役員 CFO 河原 亮 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区六本木六丁目10番1号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-6372-1265 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役 上級執行役員 CFO 河原 亮 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E33586 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 44800 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社メドレー | |
| Filer name in english | FilingDateInstant | MEDLEY,INC. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2025-01-01 | |
| Current period end date | FilingDateInstant | 2025-06-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-01-01 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |